Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. - Wikidata - wikimedia - TriplyDB

Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis.

Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis.

http://www.wikidata.org/entity/Q44973887

about

Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive Review Clodronate: new directions of use Decrease of CD68 Synovial Macrophages in Celastrol Treated Arthritic Rats Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis.Systemic but no local effects of combined zoledronate and parathyroid hormone treatment in experimental autoimmune arthritis.Osteoclast activity modulates B-cell development in the bone marrow Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection.Kcnn4 is a regulator of macrophage multinucleation in bone homeostasis and inflammatory disease Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.Using hand bone mass measurements to assess progression of rheumatoid arthritis.Rheumatic diseases: the effects of inflammation on bone.The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis.Mechanisms of Disease: the link between RANKL and arthritic bone disease.Pharmacodynamics of bisphosphonates in arthritis.Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts and Osteoblasts.Rheumatoid Arthritis Exacerbates the Severity of Osteonecrosis of the Jaws (ONJ) in Mice. A Randomized, Prospective, Controlled Animal Study.RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro.Is RANKL inhibition both anti-resorptive and anabolic in rheumatoid arthritis?Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis.Downregulation of miR-106b attenuates inflammatory responses and joint damage in collagen-induced arthritis.RANKL: A therapeutic target for bone destruction in rheumatoid arthritis.Parthenolide inhibits pro-inflammatory cytokine production and exhibits protective effects on progression of collagen-induced arthritis in a rat model.Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial.Immunoporosis: Immunology of Osteoporosis-Role of T Cells.Evaluation of cartilage and bone degradation in a murine collagen antibody-induced arthritis model.Kinetic changes of regulatory B10 cells in collagen-induced arthritis could be regulated by cytokines IFN-γ and TGF-β1.Jatrorrhizine Hydrochloride Suppresses Proliferation, Migration, and Secretion of Synoviocytes In Vitro and Ameliorates Rat Models of Rheumatoid Arthritis In Vivo.

P2860

Q26774874-8977F6B3-A163-458C-A03E-C83777F0E1A8 Q26775773-1BB9FDA2-EF59-4872-B206-B73685F569B7 Q27345563-ADF0DD95-E0CC-4C2A-A143-0AD4603578CC Q34001621-6DAD75C6-EDB2-4548-A733-E76351A5300D Q34413330-D039117D-F023-4112-83BD-E9A10DE14742 Q35122997-5FE2BFCE-FCB2-455E-8C56-B692D01139A6 Q35348955-FFC7763E-20E7-4599-8898-C3CAE4274D99 Q35572441-09D3C2BF-F381-4CBE-9DB1-3E1775A1A8DB Q35754345-5882D95E-7144-4979-BC84-D3A278062C3B Q36052572-114D364A-EC40-4EDC-9E2B-26812CA04C60 Q36059378-3FDD7487-0BB8-4D9A-9388-03156DD04553 Q36324975-DD185B54-E763-46FD-A133-FDE241F6A18F Q36337775-3E1DD0C6-1DD7-40B0-9B20-8D310665E450 Q36577375-A09681A1-B833-4874-B783-52EF372B26CA Q37973356-5A8BAA76-8EC0-4A14-B9F3-3FFF071747F6 Q38593977-12D6E20B-1761-41BA-87C0-2595C12741C1 Q39942547-C0AA6D16-C13E-4578-B02D-C90C6AD3D43E Q42136336-5E72FCC7-4AAE-4A23-A9A0-1EE834A813FE Q42541450-2BC512A6-B5F3-4153-876B-F6F4C5321E11 Q46288657-E8128258-7A20-458D-941E-C3C49467B516 Q47731229-CB163151-74D9-4CFD-A42A-822FD19489D0 Q50207113-C6583F37-7325-4029-9257-D4F5299C7AE2 Q50220083-5A974B49-A5E8-4EA1-B4BF-B0D63C8B0D4E Q51237000-C005FD64-1BD0-4204-9DFF-4B82EB95E8A1 Q52576095-2A10D86A-3B5B-4CE0-8EF4-F0382C5933D9 Q53436330-C43B5151-3719-41C7-BDAF-6C38A0599E66 Q53452331-741F9D90-270A-4303-8322-C6514A42A61A Q54968721-4C91308B-B2E3-4E36-A64F-D2056C6D0D91

P2860

Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis.

http://www.wikidata.org/entity/Q44973887

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Targeting osteoclasts with zol ...... in collagen-induced arthritis.

@en

Targeting osteoclasts with zol ...... in collagen-induced arthritis.

@nl

type

label

Targeting osteoclasts with zol ...... in collagen-induced arthritis.

@en

Targeting osteoclasts with zol ...... in collagen-induced arthritis.

@nl

prefLabel

Targeting osteoclasts with zol ...... in collagen-induced arthritis.

@en

Targeting osteoclasts with zol ...... in collagen-induced arthritis.

@nl

P1433

Q44973887-EB2F8046-ADDA-4818-A99E-DE375B120D86

P1476

Q44973887-920C8697-F758-475A-A514-97BE022A830D

P2093

Q44973887-30D4E16C-3C78-4DDB-A7C3-D2C7DE6D5828

Q44973887-55028436-831C-4811-809B-48ACC0D805A4

Q44973887-6F621CF6-5C5D-40E2-BAA8-3F20693D1E6F

Q44973887-889C9225-76D6-4AC8-ADD8-CE8E4728975D

Q44973887-B817741F-0956-4419-B1C8-4719ECD686A9

P2860

Q44973887-10526620-35E4-463C-9C4B-8DED09220D84

Q44973887-17053868-EF21-4ABA-9C00-98B609DC4035

Q44973887-291BA044-6718-4CC9-8230-27A21D1CAE9E

Q44973887-C6CAC057-4F8B-4641-B2FD-01AC0457F57F

P304

Q44973887-20238EB5-3539-4FEC-A703-81A4CF717D86

P31

Q44973887-329693AD-9A7A-4C14-B684-83CC10D73CDB

P356

Q44973887-57F0516F-0590-4A52-BB75-6A973E6FDC2D

P433

Q44973887-6DA129DA-CFB3-4E48-BD2D-BDB2DCF13BCA

P478

Q44973887-30C1C79A-6D55-4010-8639-C10417155708

P50

Q44973887-5940AE33-D4AA-4CEC-8127-3FD485F37C6E

Q44973887-B5EBB3A2-02E4-4D6F-92EF-35C7178E9BAE

P577

Q44973887-FEC51250-C36A-41F6-A01F-C0A410C4C282

P5875

Q44973887-D0E7AD7E-EC03-403E-ADB3-4FFC281E91F2

P698

Q44973887-1AA24523-EF66-4675-BB44-FFD0864D81D0

P356

P1433

Arthritis and Rheumatism

P1476

Targeting osteoclasts with zol ...... in collagen-induced arthritis

@en

P2093

Evan Romas

http://www.w3.org/2001/XMLSchema#string

Jonathan R Green

http://www.w3.org/2001/XMLSchema#string

Markus Glatt

http://www.w3.org/2001/XMLSchema#string

Stephen Schlict

http://www.w3.org/2001/XMLSchema#string

T John Martin

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis.

Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis.

Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice.

P304

2338-2346

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.20382

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P50

Natalie A. Sims

Matthew T Gillespie

P577

2004-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8461508

http://www.w3.org/2001/XMLSchema#string

P698

15248235

http://www.w3.org/2001/XMLSchema#string